Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression

13 Dec 2022

Abstract excerpt

Bromodomain and extra-terminal tail (BET) proteins have been identified as potential epigenetic targets in cancer, including glioblastoma. These epigenetic modifiers link the histone code to gene transcription that can be disrupted with small molecule BET inhibitors (BETi). With the aim of developing rational combination treatments for glioblastoma, we analyzed BETi-induced differential gene expression in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36513631
DOI: 10.1038/s41419-022-05497-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expressionPMID 36513631Read ↗

BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expressionSemantic proximity Read ↗

BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cellsSemantic proximity Read ↗

Bromodomain and Extraterminal Domain (BET) Protein Inhibition Hinders Glioblastoma Progression by Inducing Autophagy-Dependent DifferentiationSemantic proximity Read ↗

CPI203, a BET inhibitor, down-regulates a consistent set of DNA synthesis genes across a wide array of glioblastoma linesSemantic proximity Read ↗

R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition.Semantic proximity Read ↗

Targeting BET Bromodomains in CancerSemantic proximity Read ↗

Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System TumorsSemantic proximity Read ↗

The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasionSemantic proximity Read ↗

BRD4: New hope in the battle against glioblastomaSemantic proximity Read ↗

Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genesSemantic proximity Read ↗

Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)Semantic proximity Read ↗

Targeting the Bromodomain of BRG-1/BRM Subunit of the SWI/SNF Complex Increases the Anticancer Activity of Temozolomide in GlioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.